🇺🇸 FDA

Intelligence · Patent portfolio

Chongqing Precision Biotech Patents

Full USPTO pharma patent portfolio for Chongqing Precision Biotech — grant dates, expiration, and drug cross-links.

Patents
158
Expiring ≤24m
2

Quick answer

Chongqing Precision Biotech has 158 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 2 expire within 24 months — use filters for patent-cliff planning.

Page 2 of 4

  1. US 11268065

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11225641

    Probiotic Bifidobacterium strain

    Expires Mon Jan 13 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11191935

    Implant delivery system with hydration promotor capability

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11186822

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11142750

    Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11129791

    Drug delivery device

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11096996

    Cancer vaccines and vaccination methods

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11078245

    Colon and pancreas cancer peptidomimetics

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11053484

    Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11021576

    Polymeric stabilizing formulations

    Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11008548

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11001641

    Monoclonal antibody therapy for pancreas cancer

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10973862

    Bifidobacterium longum for treating obesity and associated metabolic disorders

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10851358

    Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10813366

    Bifidobacterium longum NCIMB 41676

    Expires Mon Oct 22 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10799535

    Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10800833

    Co-stimulatory domains for use in genetically-modified cells

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10792481

    Implantable drug delivery device

    Expires Mon Oct 01 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10758595

    Treatment of retinitis pigmentosa using engineered meganucleases

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10745665

    Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10688056

    Implantable medical devices for extended release of therapeutic agents

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10689719

    Bifidobacterium longum

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10689443

    Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10662416

    Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10662440

    Self-limiting viral vectors encoding nucleases

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10653169

    Food thickening agent, method for producing food thickening agent

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10603363

    Treatment of retinitis pigmentosa using engineered meganucleases

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10597739

    Probiotic bifidobacterium strain

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10533040

    Colon and pancreas cancer peptidomimetics

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10525248

    Apparatus and method for promoting fluid uptake into an implant

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10479868

    Polymeric stabilizing formulations

    Expires Mon Nov 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10422807

    Indirect homogeneous mobility shift assays for the detection of biologics in patient samples

    Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10364295

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10351628

    Antibody fragments, compositions and uses thereof

    Expires Mon Jul 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10327461

    Food thickening agent, method for producing food thickening agent

    Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10214721

    Method for making culture medium

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10105523

    Implantable drug delivery device

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10093900

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10093899

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10045943

    Implantable medical devices for extended release of therapeutic agents

    Expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10041053

    Rationally-designed single-chain meganucleases with non-palindromic recognition sequences

    Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10023650

    Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10016388

    Ophthalmic lens, intraocular lens, and ophthalmic lens package having ophthalmic lens

    Expires Mon Jul 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10006052

    Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10000746

    LAGLIDADG homing endonuclease cleaving the T cell receptor alpha gene and uses thereof

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9993502

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9993501

    Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9975952

    Antibody fragments, compositions and uses thereof

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Chongqing Precision Biotech have?

158 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Chongqing Precision Biotech patents expire?

2 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.